Clearside Biomedical(US:CLSD)2024-08-12 20:15Revenue Performance - License and other revenue for Q2 2024 was $90,000, a decrease from $1.0 million in Q2 2023[5]. Expenses - Research and development expenses for Q2 2024 were $4.6 million, down from $4.9 million in Q2 2023, primarily due to reductions in the CLS-AX program and SCS Microinjector development[5]. - Total operating expenses for Q2 2024 were $7.68 million, compared to $8.29 million in Q2 2023[12]. - Non-cash interest expense remained constant at $2.3 million in both Q2 2024 and Q2 2023[5]. Financial Performance - Net loss for Q2 2024 was $7.6 million, or $0.10 per share, compared to a net loss of $9.1 million, or $0.15 per share, in Q2 2023[5]. - As of June 30, 2024, Clearside's cash, cash equivalents, and short-term investments totaled $29.4 million, expected to fund operations into Q3 2025[6]. Clinical Trials and Partnerships - Topline data from the Phase 2b ODYSSEY clinical trial of CLS-AX is expected in late Q3 2024[2]. - Clearside's Asia-Pacific partner, Arctic Vision, reported positive results from its Phase 3 trial for XIPERE, with NDAs accepted for review in Australia and Singapore[3]. - 87.7% of eyes treated with XIPERE did not require additional corticosteroid injections for 6 months after a single dose[2]. - Clearside's gene therapy partner, REGENXBIO, plans to initiate a global pivotal trial in H1 2025 for diabetic retinopathy[3].